UY39110A - Compuestos para su uso en infecciones víricas - Google Patents

Compuestos para su uso en infecciones víricas

Info

Publication number
UY39110A
UY39110A UY0001039110A UY39110A UY39110A UY 39110 A UY39110 A UY 39110A UY 0001039110 A UY0001039110 A UY 0001039110A UY 39110 A UY39110 A UY 39110A UY 39110 A UY39110 A UY 39110A
Authority
UY
Uruguay
Prior art keywords
compounds
viral infections
virus
treatment
viral infection
Prior art date
Application number
UY0001039110A
Other languages
English (en)
Inventor
María Fernández-Sousa Jose
Avilés Marín Pablo
Losada González Alejandro
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of UY39110A publication Critical patent/UY39110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de una infección vírica, en donde el virus se selecciona entre la familia Orthomyxoviridae o en donde el virus es el virus del Nilo occidental.
UY0001039110A 2020-03-02 2021-03-02 Compuestos para su uso en infecciones víricas UY39110A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25

Publications (1)

Publication Number Publication Date
UY39110A true UY39110A (es) 2021-09-30

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001039109A UY39109A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias
UY0001039110A UY39110A (es) 2020-03-02 2021-03-02 Compuestos para su uso en infecciones víricas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001039109A UY39109A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias

Country Status (16)

Country Link
US (2) US20230295236A1 (es)
EP (2) EP4114435A1 (es)
JP (2) JP2023517535A (es)
KR (2) KR20220151643A (es)
CN (2) CN115461067A (es)
AU (2) AU2021232535A1 (es)
BR (2) BR112022016604A2 (es)
CA (2) CA3169540A1 (es)
CL (2) CL2022002396A1 (es)
CO (2) CO2022014031A2 (es)
IL (2) IL296068A (es)
MX (2) MX2022010926A (es)
PE (2) PE20230606A1 (es)
TW (2) TW202146038A (es)
UY (2) UY39109A (es)
WO (2) WO2021175857A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
MXPA02009943A (es) 2000-04-07 2003-04-25 Univ Pennsylvania Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
JP2023517535A (ja) 2023-04-26
CN115666616A (zh) 2023-01-31
BR112022016675A2 (pt) 2022-10-11
US20230159594A1 (en) 2023-05-25
KR20220151643A (ko) 2022-11-15
CO2022014031A2 (es) 2022-10-21
KR20220150350A (ko) 2022-11-10
MX2022010921A (es) 2022-09-29
CL2022002396A1 (es) 2023-06-30
WO2021175831A3 (en) 2021-10-14
PE20230606A1 (es) 2023-04-10
AU2021231197A1 (en) 2022-10-06
EP4114433A2 (en) 2023-01-11
EP4114435A1 (en) 2023-01-11
TW202146038A (zh) 2021-12-16
IL296069A (en) 2022-11-01
CA3169544A1 (en) 2021-09-10
UY39109A (es) 2021-09-30
WO2021175831A2 (en) 2021-09-10
MX2022010926A (es) 2022-09-29
WO2021175857A1 (en) 2021-09-10
US20230295236A1 (en) 2023-09-21
CN115461067A (zh) 2022-12-09
PE20230412A1 (es) 2023-03-07
AU2021232535A1 (en) 2022-10-06
CA3169540A1 (en) 2021-09-10
CL2022002395A1 (es) 2023-06-30
BR112022016604A2 (pt) 2022-10-11
TW202144381A (zh) 2021-12-01
CO2022014093A2 (es) 2022-11-18
JP2023517536A (ja) 2023-04-26
IL296068A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
CO2022014031A2 (es) Compuestos para su uso en infecciones víricas
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
CL2018001207A1 (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
AR057623A1 (es) Materiales y metodos para el tratamiento de las infecciones virales
GT201300093A (es) Compuestos antivirales
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
ECSP14013315A (es) Inhibidores de aplicación viral
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
ECSP13010937A (es) Compuestos antivirales
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
EA201891975A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen